Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-02-17 07:00 |
Kommuniké från extra bolagsstämma i Orexo AB den 16 februari 2011
|
Swedish | 92.7 KB | ||
| 2011-02-16 08:01 | English | 523.2 KB | |||
| 2011-02-16 08:00 | Swedish | 510.6 KB | |||
| 2011-01-14 08:00 |
Orexo och Invida ingår avtal avseende Abstral™ i Asien och Stillahavsområdet
|
Swedish | 115.1 KB | ||
| 2011-01-14 08:00 |
Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific
|
English | 117.0 KB | ||
| 2011-01-13 08:00 |
Anders Lundström utsedd till ny VD för Orexo
|
Swedish | 100.5 KB | ||
| 2011-01-13 08:00 |
Anders Lundström to be the new CEO of Orexo
|
English | 103.5 KB | ||
| 2011-01-11 12:00 |
Notice of Extraordinary General Meeting of Orexo AB, February 16, 2011
|
English | 70.1 KB | ||
| 2011-01-11 12:00 |
Kallelse till Orexo ABs extra bolagsstämma den 16 februari 2011
|
Swedish | 67.1 KB | ||
| 2011-01-10 08:00 |
FDA Approval for Abstral (Fentanyl) Sublingual Tablets - US launch planned for …
|
English | 161.5 KB | ||
| 2011-01-10 08:00 |
Abstral (sublingualt fentanyl) godkänt av FDA i USA – USA-lansering planerad fö…
|
Swedish | 149.7 KB | ||
| 2010-12-16 09:00 |
Orexo and Boehringer Ingelheim report progress in their pain and inflammatory d…
|
English | 122.3 KB | ||
| 2010-12-16 09:00 |
Orexo och Boehringer Ingelheim rapporterar framsteg i samarbetet som syftar til…
|
Swedish | 126.0 KB | ||
| 2010-12-14 09:00 |
Orexo reports phase I trial results for OX219, a novel sublingual tablet formul…
|
English | 100.3 KB | ||
| 2010-12-14 09:00 |
Orexo rapporterar fas I-resultat för OX219, en ny sublingual tablettformulering…
|
Swedish | 97.4 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
